ABBVIE INC (ABBV)

Buying the Dip in These 3 Undervalued Dividend Stocks

All three of these stocks look intriguing.

Buying the Dip in These 3 Undervalued Dividend Stocks

All three of these stocks look intriguing.

3 Dividend Kings Down 11% You’ll Regret Not Buying on the Dip

These dividend stocks have proved time and again why they're the cream of the crop and will rise to the top once more.

Why I Keep Buying This Ultra-High-Yielding ETF for Passive Income

The JPMorgan Equity Premium Income ETF produces a lucrative monthly passive income stream.

These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?

Small-cap stocks have been the market laggards but these standouts showed how to beat even top-tier tech names at their own game.

The Bad News Heading Into AbbVie's First-Quarter Earnings Report

AbbVie is working against numerous biosimilar versions of Humira. But one has "stepped up dramatically."

Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis

− Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15 mg)...

Steady Income, Steady Growth: 7 Blue-Chip Dividend Stocks to Buy Now

With an already tense situation becoming even more troubling, now’s the time to consider blue-chip dividend stocks to buy.

Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug

The company was testing a potential treatment for schizophrenia in rabbits, but found a notable side effect.

See Which Of The Latest 13F Filers Holds AbbVie

Is AbbVie a Millionaire Maker?

Everything is going according to plan, and more growth is on the way.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors

Notable Friday Option Activity: TGT, ABBV, DIS

AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine

- Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and...

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks were among the worst performers in 2023. And so far in 2024, inv...

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024

In a stock picker’s market, here are three biotech stocks analysts believe have a chance to outperform the market in 2024.

May 31st Options Now Available For AbbVie (ABBV)

The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today

Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.

The Law Offices of Frank R. Cruz Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors

3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade

Income-seeking investors can look forward to steady payout raises from these pharma stocks.

3 No-Brainer Dividend Stocks to Buy in April

Income investors will find a lot to like about these stocks.

Noteworthy Thursday Option Activity: AXNX, ABBV, ROKU

Thursday's session: top gainers and losers in the S&P500 index

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Thursday.

Which S&P500 stocks are moving on Thursday?

Stay informed about the performance of the S&P500 index in the middle of the day on Thursday. Uncover the top gainers and losers in today's session for valuable insights.

May 24th Options Now Available For AbbVie

Passive Income Perfection: 7 Dividend Stocks to Generate $50,000 Per Year

These seven dividend stocks provide a base for $50,000 in income per year for dedicated investors with patience.